Key points are not available for this paper at this time.
Design
Review
No takes yet. Share an insight, caveat, or question.
No immediate change to HF management; leaves open validation of gap junction targets in prospective trials.
Saffitz et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: